To synthesize current evidence on the genetic predictors of supraventricular tachycardia (SVT), emphasizing the significance of translational relevance and personalized medicine.
Key Findings:
SVT exhibits subtype-specific genetic architecture with implications for clinical practice.
AVNRT shows familial clustering and polygenic susceptibility with GWAS signals implicating developmental pathways.
Accessory pathway-mediated AVRT/WPW has a clear genotype-to-substrate relationship with common and rare variations.
The genetic basis of focal atrial tachycardia is underpowered and heterogeneous.
Current clinical utility of genetics is highest in syndromic and cardiomyopathy-associated SVT, impacting treatment strategies.
Interpretation:
Genetic discoveries are shifting the understanding of SVT from a functional arrhythmia to a spectrum of inherited electrophysiologic and myocardial diseases, influencing treatment strategies.
Limitations:
Routine genetic testing is not indicated for most isolated SVT cases.
Barriers include incomplete phenotype-genotype correlation, modest effect sizes for common variants, and potential future research directions.
Conclusion:
Phenotype-guided evaluation and improved functional models may enable targeted, patient-centered personalization in specific SVT presentations, highlighting the importance of genetic testing in certain populations.
